Peripheral Blood Leukocytes as a Surrogate Marker for Cisplatin Drug Resistance: Studies of Adduct Levels and the Repair Gene ERCC1

  • Ricardo J. Parker
  • Miriam C. Poirier
  • Freida Bostick-Bruton
  • Justine Vionnet
  • Vilhelm A. Bohr
  • Eddie Reed
Part of the Basic Life Sciences book series (BLSC, volume 53)

Abstract

Cisplatin and its analogs are potent chemotherapeutic agents in the treatment of ovarian cancer, testicular cancer, and other malignancies. Studies by this group have shown that the level of platinum-DNA adduct formed in leukocyte DNA is directly related to disease response in ovarian cancer (Reed et al, 1987) and testicular cancer (Reed et al, 1988a), and that the level of adduct attained is influenced by the persistence of the adduct in leukocyte precursors in some patients for no less than 28 days (Reed et al, 1986). Because this persistence has been observed in some patients but not in others (Reed et al, 1986), we have been interested in the study of those factors that may influence persistence, and whether these factors are directly related to clinical parameters and/or subcellular parameters of cisplatin drug resistance. We have assessed the relative contribution of clinical parameters to disease response in a cohort of patients with ovarian cancer, and we compare those data to platinum-DNA adduct measurements in leukocyte DNA from these same individuals.

Keywords

Toxicity Furnace Graphite Platinum Leukemia 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bohr, V.A., Chu, E.H.Y., van Duin, M., Hanawalt, P.C., and Okumoto, D. S., 1988, Human repair gene restores normal pattern of preferential DNA repair in repair defective CHO cells, Nucleic Acids Res, 16: 7397.PubMedCrossRefGoogle Scholar
  2. Conover, W.J., 1980, “Practical Non-Parametric Statistics,” 2nd ed. Johns Wiley and Sons, New York.Google Scholar
  3. Davis, L.G., Dibner, M.D., and Battey, J.F., 1986, “Basic Methods in Molecular Biology,” Elsevier, New York.Google Scholar
  4. Fairchild, C.R., Ivy, S.P., Rushmore, T., Lee, G., Koop, Goldsmith, M.E., Myers, C.E., Farber, E., and Cowan, K.H., 1987, Carcinogen induced mdr expression is associated with xenobiotic resistance in rat preneo- plastic liver nodules and hepatocellular carcinomas. Proc. Natl. Acad. Sci. USA, 84: 7701.PubMedCrossRefGoogle Scholar
  5. Flamm, W.H., Birnsteil, M.L., and Walter, P.M.B., 1969, in: “Subcellular Components: Preparation and Fractionation,” G. Birnie and S.M. Fox, eds, Butterworth and Co., Ltd., London.Google Scholar
  6. Hoeijmakers, J.H.J., 1987, Characterization of genes and proteins involved in excision repair of human cells, J Cell Sci (Suppl 6), 111.Google Scholar
  7. Kraker, A.J., and Moore, C.W., 1988, Elevated DNA polymerase beta activity in a cis-diamminedichloroplatinum(II) resistant P388 murine leukemia cell line, Cancer Letters, 38: 307.PubMedCrossRefGoogle Scholar
  8. Lu, Y., Han, J., and Scanlon, K.J., 1988, Biochemical and molecular properties of cisplatin-resistant A2780 cells grown in folinic acid, J Biol Chem, 263: 4891.PubMedGoogle Scholar
  9. Ozols, R.F., Ostchega, Y., Myers C.E., and Young, R.C., 1985, High dose cisplatin in hypertonic saline in refractory ovarian cancer patients, J Clin Oncol, 3: 1246.PubMedGoogle Scholar
  10. Ozols, R.F., Ostchega, Y., Curt, G.A., and Young, R.C., 1987, High dose carboplatin in refractory ovarian cancer patients, J Clin Oncol, 5: 197.PubMedGoogle Scholar
  11. Reed, E., 1989, Cisplatin. in “Cancer Chemotherapy and Biological Response Modifiers Annual - Volume 11,” H.M. Pinedo, B.A Chabner, and D.L. Longo, eds, Elsevier Science Publishers B.V., Amsterdam, in press.Google Scholar
  12. Reed, E., Yuspa, S.H., Zwelling, L.A., Ozols, R.F., and Poirier, M.C., 1986, Quantitation of cisplatin-DNA intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy, J. Clin. Invest., 77: 545.PubMedCrossRefGoogle Scholar
  13. Reed, E., Ozols, R.F., Tarone, R., Yuspa, S.H., Poirier, M.C., 1987, Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy, Proc. Natl. Acad. Sci. USA, 84: 5024.PubMedCrossRefGoogle Scholar
  14. Reed, E., Ozols, R.F., Tarone, R., Yuspa, S.H., Poirier, M.C., 1988a, The measurement of cisplatin-DNA adduct levels in testicular cancer patients, Carcinogenesis, 9: 1909.PubMedCrossRefGoogle Scholar
  15. Reed, E., Sauerhoff, S., and Poirier, M.C., 1988b, Quantitation of platinum-DNA binding in human tissues following therapeutic levels of drug exposure - A novel use of graphite furnace spectrometry, Atomic Spectroscopy, 9: 93.Google Scholar
  16. Reed, E., Poirier, M.C., Young, R.C., Ozols, R.F., 1988c, High dose cisplatin in hypertonic salines Toxicity versus therapeutic benefit, in: “Organ Directed Toxicities of Anti-Cancer Drugs,” H.P. Hacker, J.S. Lazo, and T.R. Tritton, eds., Martinus Nijhoff Publishers, Boston.Google Scholar
  17. Scanlon, K.J., and Kashani-Sabet, M., 1988, Elevated expression of thymidylate synthase cycle genes in cisplatin-resistant human ovarian carcinoma A2780 cells, Proc Natl Acad Sci USA, 85: 650.PubMedCrossRefGoogle Scholar
  18. Van Duin, M., de Wit, J., Odijk, H., Westerveld, A., Yasui, A., Koken, M.H.M., Hoeijmakers, J.H.J., and Bootsma, D., 1986, Molecular characterization of the human excision repair gene ERCC-1: cDNA cloning and amino acid homology with the yeast DNA repair gene RADIO, Cell, 44: 913.PubMedCrossRefGoogle Scholar
  19. Westerveld, A., Hoeijmakers, J.H.J., van Duin, M., de Wit, J., Odijk, H., Pastink, A., Wood, R.D., and Bootsma, D., 1984, Molecular cloning of a human DNA repair gene, Nature, 310: 425.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1990

Authors and Affiliations

  • Ricardo J. Parker
    • 1
  • Miriam C. Poirier
    • 2
  • Freida Bostick-Bruton
    • 1
  • Justine Vionnet
    • 1
  • Vilhelm A. Bohr
    • 1
  • Eddie Reed
    • 1
  1. 1.Division of Cancer TreatmentNational Cancer InstituteBethesdaUSA
  2. 2.Divisiono of Cancer EtiologyNational Cancer InstituteBethesdaUSA

Personalised recommendations